Key result
High-dose maternal valacyclovir stabilized fetal CMV lesions, but newborn viral load did not differ by treatment duration.
Why the study?
There is currently no validated treatment for fetal CMV, though preliminary studies suggest maternal valacyclovir may improve outcomes in moderately symptomatic fetuses.
Does maternal high-dose valacyclovir improve fetal outcomes and reduce newborn blood viral load in pregnancies with fetal CMV infection?
Observational (n=8)
Does maternal high-dose valacyclovir improve fetal outcomes and reduce newborn blood viral load in pregnancies with fetal CMV infection?
In a small case series of fetal CMV infection, maternal high-dose valacyclovir was well-tolerated and fetal lesions remained stable, though newborn viral load was unchanged regardless of treatment duration.
Answers are grounded in this paper and cite their sources.
Maternal high-dose valacyclovir may stabilize fetal CMV lesions; hypothesis-generating and requires RCTs before any practice change.
Background/objective Currently, there is no validated treatment for fetal cytomegalovirus (CMV). Two studies suggest that high-dose maternal valacyclovir decreases fetal viral load and improves outcomes in moderately-symptomatic fetuses. We offered valacyclovir in cases of fetal infection lacking ultrasound abnormalities or with non-severe infection. Maternal tolerability, fetal outcome and newborn blood viral load were evaluated in pregnancies of mothers receiving valacyclovir.Study design We performed a case series including 8 pregnancies with fetal CMV classified as unaffected/mildly-moderately affected. Mothers received valacyclovir (8 g/24h) from fetal infection diagnosis to delivery. Standard newborn evaluation was performed, and viremia was determined in the first 48 h of life and compared according to length of maternal treatment and presence/absence of prenatal anomalies.Results Valacyclovir was administered at a median gestational age of 26.5 weeks (23.8–33.1) in 3 cases without fetal abnormalities, and 5 with mild/moderate abnormalities. Three were 3 first trimester primary infections, one non-primary infection, and in 4 the type of infection was unknown. Valacyclovir was well-tolerated. Fetal features did not progress. Three newborns were asymptomatic, and one was severely affected (bilateral chorioretinitis). The median newborn viral load (IQR) was 502 IU/mL (231–191781) with lower levels when maternal treatment was administered ≥10 weeks, and in cases without fetal abnormalities [median 234 IU/mL (228–711) vs. 4061 (292–510500) p = .18; and 234 IU/mL (228–379500) vs. 711 IU/mL (292–4061) p = .65, respectively], these differences being non-significant.Conclusions Fetal CMV lesions remained stable with high-dose maternal valacyclovir. Newborn viral load was unchanged despite treatment duration and fetal/neonatal abnormalities.Summary Fetal cytomegalovirus lesions remained stable with high-dose maternal valacyclovir. Newborn viral load was unchanged despite treatment duration and fetal/newborn abnormalities.
No takes yet. Share an insight, caveat, or question.
Goncé et al. (2020) conducted an observational in Fetal cytomegalovirus (CMV) infection (n=8). High-dose valacyclovir vs. Shorter treatment duration (<10 weeks) or presence of fetal abnormalities was evaluated on Newborn blood viral load and fetal outcome. High-dose maternal valacyclovir stabilized fetal CMV lesions, but newborn viral load did not differ by treatment duration.
Synapse has enriched 10 related papers. Consider them for comparative context: